Lowering the prophylactic platelet transfusion threshold: A prospective analysis

被引:49
作者
Lawrence, JB [1 ]
Yomtovian, RA [1 ]
Hammons, T [1 ]
Masarik, SR [1 ]
Chongkolwatana, V [1 ]
Creger, RJ [1 ]
Manka, A [1 ]
Lazarus, HM [1 ]
机构
[1] Univ Hosp Cleveland, Cleveland, OH 44106 USA
关键词
platelet transfusion; hemorrhage; thrombocytopenia; leukemia; blood & marrow transplant;
D O I
10.3109/10428190109057955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The 20 x 10(9)/L threshold for prophylactic platelet transfusion may be unnecessarily high. Few prospective studies. however, in which other trigger values were tested have been published. In this study all hospitalized, thrombocytopenic adult hematology-oncology patients in our institution were prospectively evaluated daily for hemorrhage and platelet transfusion during a one year period; no patients were excluded for bleeding or infectious problems. By design, during the initial six-months: (baseline period), the prophylactic platelet transfusion trigger was 20 x 10(9)/L; for the second six-months (study period) this threshold was changed to 10 x 10(9)/L. Patients studied during the two periods did not differ significantly in age, gender. diagnosis. blood or marrow transplant status, and duration of neutropenia. Compliance with the thresholds was 95.6% (baseline period) and 93.5% (study period). For patients with platelet counts under 20 x 10(9)/L. the mean use of platelet transfusions per patient per day was significantly lower in the study period (4.47) than in the baseline period (6.48: p<0.001). Both mean prophylactic (1.54/patient-day) and therapeutic (2.93/patient-day) platelet transfusions were reduced in the study period compared with the baseline period (2.16 and 4.22/patient-day, respectively). Hemorrhage was slightly reduced in the study period compared with the baseline period: major hemorrhage, 15.2% vs. 18.4% (p=0.014): minor hemorrhage. 63.6% vs. 70.1% (p<0.001). Thus, hemorrhage was not increased with the lower trigger level. A 10 x 10(9)/L prophylactic platelet transfusion threshold value is safe and effective.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 49 条
[1]   BLEEDING DUE TO THROMBOCYTOPENIA IN ACUTE LEUKEMIAS AND REEVALUATION OF THE PROPHYLACTIC PLATELET TRANSFUSION POLICY [J].
ADERKA, D ;
PRAFF, G ;
SANTO, M ;
WEINBERGER, A ;
PINKHAS, J .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1986, 291 (03) :147-151
[2]   Trigger factors for prophylactic platelet transfusion [J].
Ancliff, PJ ;
Machin, SJ .
BLOOD REVIEWS, 1998, 12 (04) :234-238
[3]   BONE-MARROW TRANSPLANTATION [J].
ARMITAGE, JO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) :827-838
[4]   CONTROVERSIES IN TRANSFUSION MEDICINE - PROPHYLACTIC PLATELET TRANSFUSION THERAPY - PRO [J].
BAER, MR ;
BLOOMFIELD, CD .
TRANSFUSION, 1992, 32 (04) :377-380
[5]  
BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V257, P1777
[6]  
BEUTLER E, 1993, BLOOD, V81, P1411
[7]  
BISHOP JF, 1988, BLOOD, V71, P383
[8]  
BISHOP W, 1991, AM POETRY REV, V20, P31
[9]   HEMOSTATIC DEFECT PRODUCED BY CARBENICILLIN [J].
BROWN, CH ;
NATELSON, EA ;
BRADSHAW, MW ;
WILLIAMS, TW ;
ALFREY, CP .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (06) :265-270
[10]  
BROWN CH, 1976, BLOOD, V47, P949